160
Participants
Start Date
August 12, 2025
Primary Completion Date
April 30, 2026
Study Completion Date
May 31, 2026
Rademikibart in prefilled syringe
Participants receive 600 mg (4mL) of rademikibart administered subcutaneously.
Matching placebo in prefilled syringe
Participants receive 4mL of placebo matched to rademikibart administered subcutaneously.
RECRUITING
Columbus Clinical Services, LLC, Miami
RECRUITING
Pharmax Research of South Florida, Inc., Miami
NOT_YET_RECRUITING
Health Synergy Clinical Research, LLC, West Palm Beach
WITHDRAWN
Synergy Healthcare, Bradenton
NOT_YET_RECRUITING
University of Alabama at Birmingham Lung Health Center, Birmingham
NOT_YET_RECRUITING
University of Kansas Medical Center, Kansas City
NOT_YET_RECRUITING
University of Kansas Medical Center, Kansas City
RECRUITING
Inquest Clinical Research, Baytown
NOT_YET_RECRUITING
Acad. Chapidze Emergency Cardiology Center LLC, Tbilisi
NOT_YET_RECRUITING
Acad. G. Chapidze Emergency Cardiology Center, Tbilisi
RECRUITING
Caucasus Medical Center, Tbilisi
RECRUITING
Israel-Georgian Medical Research Clinic Healthycore, Tbilisi
NOT_YET_RECRUITING
LLC Diacor, Tbilisi
Lead Sponsor
Connect Biopharm LLC
INDUSTRY